Sarcoidosis Presenting As Late-Onset Dementia: Are Cerebrospinal Fluid Biomarkers Analyses Helpful?

2015 ◽  
Vol 63 (1) ◽  
pp. 198-200 ◽  
Author(s):  
Michele Kiesmann ◽  
Pierre Oliver Lang ◽  
Raphael Clere ◽  
Olivier Bousiges ◽  
Thomas Vogel ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Late Onset ◽  
Cerebrospinal Fluid Biomarkers ◽  
Late Onset Dementia

Asymptomatic Carriers of Presenilin-1 E318G Variant Show no Cerebrospinal Fluid Biochemical Signs Suggestive of Alzheimer’s disease in a Family with Late-onset Dementia

2018 ◽  
Vol 16 (1) ◽  
pp. 1-7
Author(s):  
Vladimiro Artuso ◽  
Luisa Benussi ◽  
Roberta Ghidoni ◽  
Soraya Moradi-Bachiller ◽  
Federica Fusco ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Late Onset ◽  
Presenilin 1 ◽  
Amyloid Peptides ◽  
Csf Levels ◽  
T Tau ◽  
Late Onset Dementia

Background: Presenilin-1 (PSEN-1) is a component of the γ-secretase complex involved in β-amyloid Precursor Protein (AβPP) processing. Usually, Alzheimer’s disease (AD)-linked mutations in the PSEN-1 gene lead to the early onset and increase the production of the aggregation-prone peptide Aβ42. However, the PSEN-1 E318G variant has an unclear pathogenic role and is recently reported as a genetic risk factor for AD. In particular, E318G variant presence correlated with increased cerebrospinal fluid (CSF) levels of Total Tau (t-tau) and Phosphorylated Tau (p-tau). Objective: We describe a large Italian family, which we followed from January 2003 to January 2018, with the late-onset AD and the E318G variant, with the aim of assessing E318G-associated CSF or plasma biochemical changes in biomarkers of dementia. Method: CSF Aβ42, t-tau and p-tau, plasma Aβ42 and Aβ40 were assessed by ELISA tests, while CSF amyloid peptides profile was investigated by mass spectrometry. Results: We did not find any changes in CSF biochemical markers (Aβ42, t-tau, p-tau and amyloid peptides) of asymptomatic E318G carriers in 2010 and 2012, but plasma Aβ40 was increased at the same times. From 2003 to 2018, no asymptomatic E318G carrier developed AD. Conclusion: Our follow-up of this family may help elucidate E318G’s role in AD and globally points to a null effect of this variant.

Late-onset epilepsy with unknown etiology: Neuropsychological profile, cerebrospinal fluid biomarkers, and quantitative EEG characteristics

2021 ◽  
Vol 429 ◽  
pp. 119123
Author(s):  
Elena Nardi Cesarini ◽  
Claudio Babiloni ◽  
Nicola Salvadori ◽  
Lucia Farotti ◽  
Claudio Del Percio ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Late Onset ◽  
Quantitative Eeg ◽  
Unknown Etiology ◽  
Neuropsychological Profile ◽  
Cerebrospinal Fluid Biomarkers

Cerebrospinal fluid biomarkers for neuropsychological symptoms in early stage of late-onset Alzheimer's disease

2014 ◽  
Vol 125 (10) ◽  
pp. 747-754 ◽  
Author(s):  
Hung-Chou Kuo ◽  
Hsiu-Chuan Yen ◽  
Chin-Chang Huang ◽  
Wen-Chuin Hsu ◽  
Hsing-Ju Wei ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Late Onset ◽  
Early Stage ◽  
Cerebrospinal Fluid Biomarkers ◽  
Neuropsychological Symptoms

scholarly journals Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease

2018 ◽  
Vol 14 (7) ◽  
pp. 869-879 ◽  
Author(s):  
Courtney L. Sutphen ◽  
Lena McCue ◽  
Elizabeth M. Herries ◽  
Chengjie Xiong ◽  
Jack H. Ladenson ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Late Onset ◽  
Neuronal Injury ◽  
Cerebrospinal Fluid Biomarkers
Sign in / Sign up

Export Citation Format

Share Document